Drug companies are also reducing some prices on Jan. 1. Merck & Co MRK.N plans to cut the list price of its heavily discounted diabetes drugs Januvia and Janumet "to align the list price more ...
The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...
AstraZeneca and Merck & Co have cemented ... are already on Lynparza’s list of approved indications. Use in ovarian and breast cancer has already put the drug firmly on course to top the $1 ...
The list price of Zepatier had been $54,600 for a course of treatment, lower than its competitors. The drug had $1.6 billion in sales in 2017. Other Merck drugs, which the company hasn't yet named ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback